FIGURE

Fig. 8

ID

ZDB-FIG-111202-28

Publication

Feng et al., 2010 - T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation

Other Figures

All Figure Page

Back to All Figure Page

Fig. 8

The Selective S1P1 Antagonist W146 Promotes Intravasation of Bcl-2-Overexpressing T-LBL Cells In Vivo

(A) Schematic drawing of the experimental strategy.

(B–G) Confocal images of EGFP-labeled blood vessels (B and E), dsRED2-labeled lymphoma cells (C and F), and the merged images of a vehicle-treated (D; n = 29) and a W146-treated transplanted animal (G; n = 18) demonstrate that W146 treatment promotes intravasation of bcl-2-overexpressing lymphoma cells (arrowheads) in vivo (cf. G to D). Note that W146 treatment also inhibited the in vivo formation of lymphoma cell aggregates (cf. F to C).

Scale bar for (B)–(G), 10 μM.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image.

Reprinted from Cancer Cell, 18(4), Feng, H., Stachura, D.L., White, R.M., Gutierrez, A., Zhang, L., Sanda, T., Jette, C.A., Testa, J.R., Neuberg, D.S., Langenau, D.M., Kutok, J.L., Zon, L.I., Traver, D., Fleming, M.D., Kanki, J.P., and Look, A.T., T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation, 353-366, Copyright (2010) with permission from Elsevier. Full text @ Cancer Cell